To provide additional evidence that the combination therapy exerted an anti-fibrotic effect in this model, we determined the expression of mediators known to play a role in the pathogenesis of IPF, including TGFβ, IL-1β, IL-13 and iNOS. This evidence concerns the gene NOS2 and idiopathic pulmonary fibrosis.